Drug Spending
Updated: 12-16-2024
For over 25 years, the HHS Office of Inspector General has conducted work to assess drug spending in HHS programs. This work covers three domains: reimbursement, program compliance, and incentive alignment. This page is a compilation of completed reports, unimplemented recommendations, enforcement actions, and industry guidance.
Additional Resources
- Series: States' Collection of Medicaid Rebates from Drug Manufacturers
- Federal Payments for Medicare Part D Catastrophic Coverage, 2006-2015
- Report: Average Sales Prices: Manufacturer Reporting and CMS Oversight (OEI-03-08-00480)
- Report: Drug Manufacturers' Noncompliance With Average Manufacturer Price Reporting Requirements (OEI-03-09-00060)
- Special Advisory Bulletin: Average Manufacturer Price and Average Sales Price Reporting Requirements
Related Podcast
- Medicare Part B Overpaid Millions for Selected Outpatient Drugs
- Manufacturer Safeguards May Not Prevent Copayment Coupon Use for Part D Drugs
- Medicare Part B Prescription Drug Dispensing and Supplying Fee Payment Rates
- Contract Pharmacy Arrangements in the 340B Drug Discount Program
- Oversight of Medicare Prescription Drug Decisions
Related Video
- Compliance Program Basics
- Federal Anti-Kickback Statute
- HHS OIG testifies on the 340B Drug Pricing Program